Araya VJ, Bolaños AM

Language: Spanish
References: 19
Page: 11-16
PDF size: 449.60 Kb.

ABSTRACT

The decrease in serum LDL with statins has been shown to reduce complications and mortality from cardiovascular disease. However, 10-20% of these patients show intolerance or resistance to achieve the goal of LDL like in patients with familial hypercholesterolemia. Studies have now been developed in search for alternative drugs for patients with severe hypercholesterolemia such as the Evolocumab. This is a monoclonal antibody directed against PCSK9, which allows reduction in serum LDL. Studies show a statistically significant decrease of up to 66% in the groups treated with Evolocumab, with or without a statin, versus placebo and/or ezetimibe. Proving to be effective over a period of 12 weeks. Although it was well tolerated, associated with side effects. However the incidence was similar is compared to the control group. The problem with these studies is due to inconsistencies in designing these and conflict of interest by their authors. Although it has been shown Evolocumab effectiveness in reducing LDL, it’s necessary to perform more research to understand its effectiveness and long-term safety and demonstrate a possible reduction in mortality. So far, the Evolocumab is a therapeutic alternative in those populations with family hipercoleterolemia who fail to achieve optimal levels of LDL.

REFERENCES

1. 1- Mortality and Causes of Death Collaborators. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 385: 117–171.

2. 2- Koren M, Scott R, Kim J, Knusel B, Liu T, Lei L, Bolognese M et al. Efficacy, safety, and tolera-bility of a monoclonal antibody to proprotein con-vertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study. Lancet 2012; 380: 1995–2006.

3. 3- Sniderman A, Tsimikas S, Fazio S. The Severe Hypercholesterolemia Phenotype: Clinical Diag-nosis, Management, and Emerging Therapies. J Am Coll Cardiol 2014; 63:1935–47.

4. 4- Thompson G. Managing homozygous familial hypercholesterolaemia from cradle to grave. At-herosclerosis Supplements 2015; 18: 16–20.

5. 5- Catapano A, Papadopoulos N. The safety of the-rapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis 2013; 228:18–28.

6. 6- Dias C, Shaywitz A, Wasserman S, Smith B, Gao B, Stolman D et al. Effects of AMG 145 on Low-Density Lipoprotein Cholesterol Levels Re-sults From 2 Randomized, Double-Blind, Pla-cebo-Controlled, Ascending-Dose Phase 1 Stu-dies in Healthy Volunteers and Hypercholestero-lemic Subjects on Statins. J Am Coll Cardiol 2012; 60:1888–98.

7. 7- Farnier M. PCSK9: From discovery to thera-peutic applications. Arch Cardiovasc Dis 2014; 107: 58–66.

8. 8- Davidson M. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipo-protein reduction. J Clin Lipidol 2013; 7: 11–15.

9. 9- Verbeek R, Stoekenbroek R, Hovingh K. PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. Eur J Pharmacol 2015; 763:38–47.

10. 10- Desai N, Giugliano R, Zhou J, Kohli P, Soma-ratne R, Hoffman E et al. AMG 145, a Monoclonal Antibody Against PCSK9, Facilitates Achieve-ment of National Cholesterol Education Pro-gram–Adult Treatment Panel III Low-Density Li-poprotein Cholesterol Goals Among High-Risk Patients An Analysis From the LAPLACE–TIMI 57 Trial (LDL-C Assessment with PCSK9 mono-clonaL Antibody Inhibition Combined With Statin thErapy–Thrombolysis In Myocardial Infarction 57). J Am Coll Cardiol 2014; 63:430–433.

11. 11- Giugliano R, Desai N, Kohli P, Rogers W, So-maratne R, Huang F et al. Efficacy, safety, and to-lerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholestero-laemia (LAPLACE-TIMI 57): a randomised, pla-cebo-controlled, dose-ranging, phase 2 study. Lancet 2012; 380: 2007–2017.

12. 12- Koren M, Lundqvist P, Bolognese M, Neutel J, Monsalvo M, Yang J et al. Anti-PCSK9 Monot-herapy for Hypercholesterolemia The MENDEL-2 Randomized, Controlled Phase III Clinical Trial of Evolocumab. J Am Coll Cardiol 2014; 63:2531–2540.

13. 13- Stein E, Giugliano R, Koren M, Raal F, Roth E, Weiss R et al. Efficacy and safety of evolocu-mab (AMG 145), a fully human monoclonal anti-body to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J 2014; 35: 2249–2259

14. 14- Sullivan D, Olsson A, Scott R, Kim J, Xue A, Gebski V et al. Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Choleste-rol Levels in Statin-Intolerant Patients The GAUSS Randomized Trial FREE. J Am Med As-soc 2012; 308:2497-2506.

15. 15- Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman S et al. Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Mo-noclonal Antibody to Proprotein Convertase Sub-tilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterole-mia The Reduction of LDL-C With PCSK9 Inhibi-tion in Heterozygous Familial Hypercholesterole-mia Disorder (RUTHERFORD) Randomized Trial. Circulation 2012; 126:2408–2417.

16. 16- Raal F, Stein E, Dufour R, Turner T, Civeira F, Burgess L et al. PCSK9 inhibition with evo-locumab (AMG 145) in heterozygous familial hy-percholesterolaemia (RUTHERFORD-2): a ran-domised, double-blind, placebo-controlled trial. Lancet 2015; 385: 331–340.

17. 17- Raal F, Honarpour N, Blom D, Hovingh GK, Xu F, Scott R et al. Inhibition of PCSK9 with evo-locumab in homozygous familial hypercholestero-laemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 385: 341–350.

18. 18- Sabatine M, Giugliano R, Wiviott S, Raal F, Blom D, Robinson J et al. Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovas-cular Events. N Engl J Med 2015; 372:1500-1509.

19. 19- Raal F, Giugliano R, Sabatine M, Koren M, Langslet G, Bays H et al. Reduction in Lipopro-tein(a) With PCSK9 Monoclonal Antibody Evo-locumab (AMG 145) A Pooled Analysis of More Than 1,300 Patients in 4 Phase II Trials. J Am Coll Cardiol 2014; 63:1278–1288.